期刊文献+

多发性骨髓瘤患者血清IL-6、TNF-α的表达及临床意义 被引量:1

Expression of Inflammatory Cytokines IL-6 and TNF-α in Multiple Myeloma Patients and Its Clinical Significance
下载PDF
导出
摘要 [目的]探讨多发性骨髓瘤(MM)患者血清炎症因子IL-6、TNF-α的表达及临床意义.[方法]2001年8月至2008年11月本院住院和门诊收治的150例MM患者为治疗组,患者入院治疗当天抽静脉血,选择年龄、性别匹配的健康体检者50例为对照组,采用放射免疫法检测血清IL-6和TNF-α.观察比较治疗组与对照组,治疗后有效组与无效组的IL-6、TNF-α的表达水平,并对其进行相关性分析.[结果]MM患者的血清IL-6、TNF-α水平随临床分期增加,其表达水平依次增高,且与对照组比较,差异有显著性(P〈0.01);治疗有效组治疗前后IL-6,TNF-α表达水平显著下降(P〈0.01),无效组则无差异(P〉0.05);MM患者血清中IL-6与TNF-α呈正相关(γ=0.732,P〈0.01).[结论]血清炎症因子IL-6、TNF-α在MM 的发生、发展中起重要的作用,可用于MM患者的病情判断和疗效监测. [Objective]To investigate the expression of serum inflammatory cytokines interleukin-6(IL-6) and tumor necrosis factor-alpha(TNF-α) in multiple myeloma(MM) patients and its clinical significance. [Methods] A total of 150 MM patients admitted from Aug. 2001 to Nov. were enrolled in this study. Radioimmunoassay was used to detect the expression of serum IL-6 and TNF-α. The expression of serum IL-6 and TNF-α was compared between two groups, and their relationship was analyzed. [Results]Serum IL-6 and TNF-α levels in MM patients increased with the increment of the clinical stage, and there was significant difference between MM group and control group( P 〈0.01). Serum IL-6 in MM patients was positively corre- lated with serum TNF-α(r = 0. 732, P 〈0.01). [Conclusion] Serum inflammatory cytokines IL-6 and TNF-α play an important role in occurrence and development of MM, and can be used to determine the condition of patients with MM and efficacy monitoring.
出处 《医学临床研究》 CAS 2010年第5期804-805,共2页 Journal of Clinical Research
关键词 多发性骨髓瘤/血液 白细胞介素6/A液 肿瘤坏死因子/血液 multiple myeloma/BL interleukin-6/BL tumor necrosis faetor/BL
  • 相关文献

参考文献8

  • 1张之南,沈悌.血液病疗效及诊断标准[M].第2版.北京:科学出版社,1998:373-380.
  • 2Durie BG,Salmon SE.A clinical staging system for multiple myeloma.Correlation of measured myeloma cell mass with presenting clinical features,response to treatment,and survival[J].Cancer,1975,36(3):842-854.
  • 3Kawano M,Hirano T,Matsuda T,et al.Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas[J].Nature,1988,332(6159):83-85.
  • 4Bharti AC,Donato N,Aggarwal BB.Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells[J].J Immunol,2003,171(7):3863-3871.
  • 5Chang H,Qi C,Yi QL,Reece D,et al.p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation[J].Blood,2005,105:358-360.
  • 6I.G.H.Schmidt-Wolf,A.Glasmacher,C.Hahn-Ast,et al.Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH:diagnostic and prognostic relevance[J].Cancer Genetics and Cytogenetics,2006,167(10):20-25.
  • 7Chang H,Xiaoying Qi,Joanna Yeung,et al.Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia[J].Leukemia Research,2008,27 (6):3126-3130.
  • 8W.J.Chng,J.M.Winkler,P.R.Greipp,et al.Ploidy status rarely changes in myeloma patients at disease progression[J].Leukemia Research,2006,30(7):266-271.

共引文献2

同被引文献14

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部